Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vunakizumab in Active Ankylosing Spondylitis
NCT04840485Phase 3Completed
- Sponsor
- Suzhou Suncadia Biopharmaceutical
- Start
- Jun 2021
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of vunakizumab in ankylosing spondylitis (AS) (3 arms), sponsored by Suzhou Suncadia Biopharmaceutical. Primary endpoint: Assessment of SpondyloArthritis international Society 20 Response at 16 weeks. Started Jun 2021; status: completed.
02
Drugs
vunakizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT04840485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04840485.